Comparative Pharmacology
Head-to-head clinical analysis: DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE versus VONTROL.
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxylamine succinate is a histamine H1 receptor antagonist with sedative properties; pyridoxine hydrochloride is a vitamin B6 derivative that acts as a coenzyme in amino acid, carbohydrate, and lipid metabolism. The combination is believed to reduce nausea and vomiting through central anticholinergic effects and pyridoxine supplementation.
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
1 tablet (doxylamine succinate 10 mg / pyridoxine hydrochloride 10 mg) orally twice daily (morning and evening), increased to three times daily if needed (one tablet in the morning, one in the afternoon, and two at bedtime). Maximum: 4 tablets per day.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
Doxylamine: terminal half-life 10-12 hours; steady state reached in 3-4 days. Pyridoxine: half-life 15-20 days for body stores, but plasma half-life of pyridoxal phosphate ~15-30 minutes.
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Doxylamine: ~60% renal as unchanged drug and metabolites; Pyridoxine: primarily renal as 4-pyridoxic acid and other metabolites. Up to 70% of pyridoxine metabolites excreted in urine within 24 hours.
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic
Antiemetic